The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
Chemoradiation
Durvalumab
KEAP1
NFE2L2
Stage III NSCLC
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
16
03
2021
revised:
25
04
2021
accepted:
30
04
2021
pubmed:
17
5
2021
medline:
10
8
2021
entrez:
16
5
2021
Statut:
ppublish
Résumé
KEAP1-NFE2L2-mutant NSCLCs are chemoradiation resistant and at high risk for local-regional failure (LRF) after concurrent chemoradiation (cCRT). To elucidate the impact of durvalumab on local-regional control, we evaluated LRF in patients with NSCLC treated with cCRT with and without durvalumab. Patients with stage III NSCLC treated with cCRT or cCRT and durvalumab who underwent tumor genomic profiling were evaluated. The incidence of LRF and outcomes of patients with and without KEAP1-NFE2L2-mutant tumors were evaluated. We analyzed 120 consecutive patients (cCRT alone, n = 54; cCRT and durvalumab, n = 66). Patients treated with cCRT alone had significantly more LRF events compared with those treated with cCRT and durvalumab, with 12-month LRF incidence of 39% (95% confidence interval [CI]: 24%-54%) and 18% (95% CI: 8%-28%), respectively (p = 0.002). Among patients treated with cCRT alone and cCRT and durvalumab, 20 patients (37%) and 18 patients (27%), respectively, had KEAP1-NFE2L2-mutant tumors. In patients treated with cCRT alone, those with KEAP1-NFE2L2-mutant tumors had worse local-regional control (p = 0.015), and on multivariate analysis, KEAP1-NFE2L2 mutation predicted for LRF (hazard ratio = 3.9, 95% CI: 1.6-9.8, p = 0.003). Nevertheless, patients with and without KEAP1-NFE2L2-mutant tumors had similar LRF outcomes (p = 0.541) when treated with cCRT and durvalumab, and mutational status did not predict for LRF (p = 0.545). Among those with KEAP1-NFE2L2-mutant tumors, cCRT and durvalumab significantly reduced the incidence of LRF compared with cCRT alone: 12-month LRF incidence of 62% (95% CI: 40%-84%) versus 25% (95% CI: 4%-46%), respectively (p = 0.021). Durvalumab after cCRT significantly improves local-regional control and reduces LRF in chemoradiation-resistant KEAP1-NFE2L2-mutant NSCLC tumors.
Identifiants
pubmed: 33992811
pii: S1556-0864(21)02158-4
doi: 10.1016/j.jtho.2021.04.019
pmc: PMC8316395
mid: NIHMS1711014
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
KEAP1 protein, human
0
Kelch-Like ECH-Associated Protein 1
0
NF-E2-Related Factor 2
0
NFE2L2 protein, human
0
durvalumab
28X28X9OKV
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1392-1402Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
JAMA Oncol. 2021 Feb 1;7(2):206-219
pubmed: 33331883
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
J Thorac Oncol. 2021 Mar;16(3):428-438
pubmed: 33301984
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Br J Cancer. 2019 Sep;121(6):490-496
pubmed: 31388183
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Radiother Oncol. 2020 Aug;149:205-211
pubmed: 32361014
Eur J Cancer. 2020 Nov;140:28-36
pubmed: 33039811
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):346-355
pubmed: 31175902
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):425-34
pubmed: 20980108
J Clin Oncol. 2016 Mar 20;34(9):953-62
pubmed: 26811519
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
J Natl Cancer Inst. 2021 Mar 1;113(3):266-273
pubmed: 32726432
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
Cancer Discov. 2020 Dec;10(12):1826-1841
pubmed: 33071215
Clin Cancer Res. 2020 Jan 1;26(1):274-281
pubmed: 31548347
J Thorac Oncol. 2019 Nov;14(11):1924-1934
pubmed: 31323387
J Thorac Oncol. 2021 Mar;16(3):395-403
pubmed: 33307193
J Thorac Oncol. 2012 Apr;7(4):716-22
pubmed: 22425920
Cell Cycle. 2018;17(14):1696-1707
pubmed: 30009666
Trends Biochem Sci. 2014 Apr;39(4):199-218
pubmed: 24647116
JAMA Oncol. 2017 Feb 1;3(2):256-259
pubmed: 27541827
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Cancer Discov. 2017 Jan;7(1):86-101
pubmed: 27663899
Ann Oncol. 2020 Dec;31(12):1746-1754
pubmed: 32866624
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821